Are there any studies that compare the clinical outcomes for xeloda monotherapy (without combination with other drugs) for KRAS mutant and KRAS wildtype patients who have metastatic unresectable colorectal cancer? I am trying to find out if the outcome is different if you are KRAS mutant. All studies I have found just group all the patients together (mutant and wild type) so I cannot tell whether there is a difference. I have looked and looked on line, and cannot find any. The drug company does not have a q&a section. Can anyone help? Or does anyone know the answer? Hubby is Codone 13 (if that helps!)
Xeloda - Searching for clinical studies for KRAS mutant status clinical outcomes?